Aug 08, 2025
Palatin Announces 1-for-50 Reverse Stock Split
May 08, 2025
Palatin Technologies Announces Closing of Reduced Public Offering
May 08, 2025
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
May 07, 2025
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
May 05, 2025
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Apr 14, 2025
Palatin Appeals NYSE American Notice of Delisting
Apr 10, 2025
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal
Apr 10, 2025
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
Mar 31, 2025
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Mar 25, 2025
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Feb 13, 2025
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Feb 10, 2025
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
Feb 07, 2025
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Jan 28, 2025
Palatin Provides Update on Anticipated 2025 Corporate Milestones
Dec 16, 2024
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Nov 14, 2024
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Nov 08, 2024
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Nov 04, 2024
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Oct 31, 2024
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Oct 07, 2024
Palatin Receives Notice of Non-Compliance from NYSE American